Skip to main navigation Skip to search Skip to main content

Protective effect of pioglitazone, a PPARγ agonist against acetaminophen-induced hepatotoxicity in rats

  • Gaurav Gupta
  • , Gopala Krishna
  • , Dinesh Kumar Chellappan
  • , Kumar Shiva Gubbiyappa
  • , Mayuren Candasamy
  • , Kamal Dua
  • International Medical University
  • A.M Reddy Memorial College of Pharmacy
  • University of Newcastle

Research output: Contribution to journalArticlepeer-review

77 Scopus citations

Abstract

Acetaminophen has a reasonable safety profile when consumed in therapeutic doses. However, it could induce hepatotoxicity and even acute liver failure when taken at an overdose. Pioglitazone, PPARγ ligand, is clinically tested and used in treatment of diabetes. PPARγ is a key nuclear hormone receptor of lipid metabolisms and regulates several gene transcriptions associated with differentiation, growth arrest, and apoptosis. The aim of our study was to evaluate the hepatoprotective activity of pioglitazone on acetaminophen-induced hepatotoxicity and to understand the relationship between the PPARγ and acetaminophen-induced hepato injury. For the experiment, Sprague-Dawley rats (160-180 g) were used and divided into four groups. Groups I and II were normal and experimental controls, respectively. Groups III and IV received the pioglitazone 20 mg/kg for 10 days. Hepatotoxicity was induced in Groups II and III on the eighth day with acetaminophen (i.p. 350 mg/kg body weight). The hepatoprotective effect was evaluated by performing an assay of the total protein, total bilirubin, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, and α-fetoprotein as well as glutathione peroxidase, lipid peroxidation, catalase, superoxide dismutase, and glutathione transferase and liver histopathology. The assay results were presented as mean and standard error of mean for each group. The study group was compared with the control group by one-way ANOVA test. A p value of <0.05 was considered significant. Pioglitazone significantly reduced the elevated level of above serum marker enzymes and also inhibits the free radical formation by scavenging hydroxyl ions. It also restored the level of LPO and significantly elevated the levels of endogenous antioxidant enzymes in acetaminophen-challenged hepatotoxicity. Liver histopathological examination showed that pioglitazone administration antagonized acetaminophen -induced liver pathological damage. Various biochemical estimations of different hepatic markers and antioxidant enzymes and histopathological studies of liver tissues glimpse a support to its significant hepatoprotective activity on acetaminophen -induced hepatotoxicity.

Original languageEnglish
Pages (from-to)223-228
Number of pages6
JournalMolecular and Cellular Biochemistry
Volume393
Issue number1-2
DOIs
StatePublished - Aug 2014
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Acetaminophen
  • Hepatotoxicity
  • Liver
  • PPAR gamma agonist
  • Pioglitazone

Fingerprint

Dive into the research topics of 'Protective effect of pioglitazone, a PPARγ agonist against acetaminophen-induced hepatotoxicity in rats'. Together they form a unique fingerprint.

Cite this